APA (7th ed.) Citation

ASV, S., RH, S., X, L., M, G., PK, A., NJ, A., . . . MD, S. (2022). Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet (London, England), 399(10319), 36. https://doi.org/10.1016/S0140-6736(21)02718-5

Chicago Style (17th ed.) Citation

ASV, Stuart, et al. "Immunogenicity, Safety, and Reactogenicity of Heterologous COVID-19 Primary Vaccination Incorporating MRNA, Viral-vector, and Protein-adjuvant Vaccines in the UK (Com-COV2): A Single-blind, Randomised, Phase 2, Non-inferiority Trial." Lancet (London, England) 399, no. 10319 (2022): 36. https://doi.org/10.1016/S0140-6736(21)02718-5.

MLA (9th ed.) Citation

ASV, Stuart, et al. "Immunogenicity, Safety, and Reactogenicity of Heterologous COVID-19 Primary Vaccination Incorporating MRNA, Viral-vector, and Protein-adjuvant Vaccines in the UK (Com-COV2): A Single-blind, Randomised, Phase 2, Non-inferiority Trial." Lancet (London, England), vol. 399, no. 10319, 2022, p. 36, https://doi.org/10.1016/S0140-6736(21)02718-5.